Inflammatory Bowel Disease: A Canadian Burden of Illness Review

Rocchi, A.; Benchimol, Eric I; Bernstein, Çharles N.; Bitton, Alain; Feagan, Brian G.; Panaccione, Remo; Glasgow, Kevin; Fernandes, Ana Carolina; Ghosh, Subrata

doi:10.1155/2012/984575

Cited by 246 publications

(188 citation statements)

References 47 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…Evalúa todo el intestino delgado en el 79% al 90% de los pacientes. Su rendimiento diagnóstico es del 38% al 83%, con una sensibilidad del 95% y una especificidad del 75%, un valor predictivo positivo del 94% al 97% y un valor predictivo negativo del 83% al 100% (23). La probabilidad de encontrar lesiones mediante este método se correlaciona positivamente con las siguientes circunstancias: hemoglobina menor de 10 g%, duración del sangrado mayor de 6 meses, más de un episodio de hemorragia y sangrado manifiesto frente a oculto (60% frente a 46%, respectivamente) (24).…”

Section: Videocápsula Endoscópica (Vce)unclassified

Sangrado del intestino delgado: enfoque y tratamiento

Sandoval-Riveros

Mindiola

Fernández

et al. 2017

Rev. Colomb. Gastroenterol.

View full text Add to dashboard Cite

Actualmente se pueden identificar lesiones del intestino delgado que antes eran inaccesibles. La principal herramienta diagnóstica es la videocápsula endoscópica por el alto valor predictivo negativo. Con los avances en los métodos endoscópicos, la clasificación de sangrado gastrointestinal ha cambiado. Es así como la definición de sangrado oscur,o que antes incluía al originado en intestino delgado, se ha relegado cuando su origen no se puede identificar tras la realización de esofagogastroduodenoscopia, colonoscopia y estudios del tracto digestivo medio, tales como videocápsula endoscópica, enteroscopia de empuje, enteroscopia profunda, enteroscopia intraoperatoria, enterorresonancia, enterotomografía, angiografía y gammagrafía.

show abstract

Section: Videocápsula Endoscópica (Vce)unclassified

Sangrado del intestino delgado: enfoque y tratamiento

Sandoval-Riveros

Mindiola

Fernández

et al. 2017

Rev. Colomb. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Ultimately, Hospitalization and surgery contribute to more than half of the economic burden of IBD to the society [4][5][6][7]. The quality of life of the patient is severely compensated with continuing symptoms, reduction in the ability to work, social stigma, bathroom access issues, difficulty with physical intimacy and restriction in career choices [8].…”

Section: Introductionmentioning

confidence: 99%

Prescription Pattern and Cost of Illness (Coi) of Inflammatory Bowel Disease (Ibd) in a Tertiary Care Hospital

Baig

Fatima

et al. 2016

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Treatment of Inflammatory Bowel disease (IBD) centers on agents used to relieve inflammatory process. None of the drugs used for IBD are curative; at best they serve to control the disease process. The potentially high costs of care associated with inflammatory bowel disease (IBD) are recognised. The Objective of the present study was to find the Prescription pattern and cost of illness (COI) of IBD in a Tertiary care Hospital.Methods: 20 IBD patients, in the order they approached the gastroenterology department, were enrolled in the study. Data regarding medication, hospitalisation, physician office visit, diagnostic costs, travel cost, the cost incurred by caregivers, work and non-work days lost were obtained. The cost of medications and other healthcare services was determined. The study was approved by the Institutional ethics committee. Results:The average cost (direct and indirect) per patient for six months was 26,394Rs. Drugs and medical supplies costs (65%) ranked first in the direct costs category followed by Diagnostic costs (18%), hospitalisation costs (15%) and lastly physician office visit costs (2%). On the other hand, Cost incurred by caregivers accounted for 45% of the total indirect costs followed by work and nonworking days lost (43%) and finally Travel costs (2%). Commonly prescribed drugs were corticosteroids and aminosalicylates followed by mucosal protectants, antibiotics and antiemetics. The most preferred route of drug administration was intravenous followed by oral. Conclusion:The average COI (direct and indirect) of IBD per patient for six months was 26,394Rs. Drugs and medical supplies accounted for largest contributions to the overall economic impact of IBD on the Healthcare system. Commonly prescribed drugs were corticosteroids and aminosalicylates followed by mucosal protectants, antibiotics and antiemetics. This study represents one of the very few studies conducted on COI of IBD. Large scale studies on economic research are required to further ascertain the impact of Rival therapies and management strategies for IBD.

show abstract

“…Inflammatory bowel disease is composed of two clinical entities, Crohn's Disease and Ulcerative Colitis and these clinical manifestations of chronic recurring inflammatory disorders of the intestinal mucosa impose a significant impact on human health and healthcare expenditures (Abraham & Cho, 2009;Kaser, Zeissig, & Blumberg, 2010). The economic costs of IBD to health care can range in the billions of dollars annually, and indeed in 2012, the economic costs in Canada were greater than 2.8 billion ($12 000/IBD patient) (Rocchi et al, 2012). Due to the significant ramifications of IBD on people's lives, it is imperative that researchers gain better insight into the pathogenesis of these disorders.…”

Section: Introductionmentioning

confidence: 99%

Considerations for Choosing Appropriate Animal Models to Study Inflammatory Bowel Disease

Uwiera¹,

Uwiera²,

Jiminez³

et al. 2016

JAS

View full text Add to dashboard Cite

This article examines several animal models used to investigate mechanisms involved in the induction and progression of inflammatory bowel disease in people. The use of appropriate animal models to study intestinal inflammation requires careful consideration as each model has strengths and limitations for investigating disease, and no single model provides a complete understanding of the disease process. In as such, it compels researchers to carefully contemplate the advantages and disadvantages of each animal model, and to consider the process of choosing the best animal model(s) as an essential component of the experimental design.

show abstract

Inflammatory Bowel Disease: A Canadian Burden of Illness Review

Cited by 246 publications

References 47 publications

Sangrado del intestino delgado: enfoque y tratamiento

Sangrado del intestino delgado: enfoque y tratamiento

Prescription Pattern and Cost of Illness (Coi) of Inflammatory Bowel Disease (Ibd) in a Tertiary Care Hospital

Considerations for Choosing Appropriate Animal Models to Study Inflammatory Bowel Disease

Contact Info

Product

Resources

About